Cargando…

The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy

PURPOSE: eIF4A is an RNA helicase that forms part of the machinery of translation initiation. Proteomic analysis demonstrated eIF4A expression to be at least two-fold greater in a radioresistant derivative of T-47D breast cancer cells compared to parental cells. Inhibition of eIF4A has previously be...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, Thomas E., Davies, Marc, Maher, John, Sarker, Debashis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451755/
https://www.ncbi.nlm.nih.gov/pubmed/32875125
http://dx.doi.org/10.1016/j.ctro.2020.07.002
_version_ 1783575043006005248
author Webb, Thomas E.
Davies, Marc
Maher, John
Sarker, Debashis
author_facet Webb, Thomas E.
Davies, Marc
Maher, John
Sarker, Debashis
author_sort Webb, Thomas E.
collection PubMed
description PURPOSE: eIF4A is an RNA helicase that forms part of the machinery of translation initiation. Proteomic analysis demonstrated eIF4A expression to be at least two-fold greater in a radioresistant derivative of T-47D breast cancer cells compared to parental cells. Inhibition of eIF4A has previously been shown to re-sensitize lymphomas to chemotherapeutic agents that cause DNA damage. The objective of this work is to investigate whether inhibition of eIF4A using silvestrol sensitizes breast cancer cells to radiotherapy in tissue culture, using T-47D as a model system. METHODS AND MATERIALS: T-47D cells were incubated in medium containing 0 nM to 1 nM silvestrol either for 24 h prior to irradiation at 0 Gy to 10 Gy, delivered by linear accelerator (LINAC) or continually for six days post irradiation. MTT viability and clonogenic assays were used to quantify response. RESULTS: Pre-treatment of T-47D cells with 1 nM silvestrol caused a 34% reduction (p = 0.014) in viability on irradiation at 2 Gy compared to treatment with a DMSO control, as assessed by MTT assay. Maintenance of cells in 1 nM silvestrol for six days following irradiation at 2 Gy caused a 58% reduction (p = <0.001) in tumor cell viability. Clonogenic assays performed on cells maintained in 1 nM silvestrol following irradiation showed a dose modifying factor (DMF) of 1.4 (p = <0.001, one-way ANOVA). CONCLUSIONS: Low concentrations of silvestrol sensitize T-47D breast cancer cells to radiation with minimal effects on unirradiated cells. This highlights the possible usefulness of eIF4A inhibition in potentiating radiation-induced damage at the tumor site without causing systemic toxicity.
format Online
Article
Text
id pubmed-7451755
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74517552020-08-31 The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy Webb, Thomas E. Davies, Marc Maher, John Sarker, Debashis Clin Transl Radiat Oncol Article PURPOSE: eIF4A is an RNA helicase that forms part of the machinery of translation initiation. Proteomic analysis demonstrated eIF4A expression to be at least two-fold greater in a radioresistant derivative of T-47D breast cancer cells compared to parental cells. Inhibition of eIF4A has previously been shown to re-sensitize lymphomas to chemotherapeutic agents that cause DNA damage. The objective of this work is to investigate whether inhibition of eIF4A using silvestrol sensitizes breast cancer cells to radiotherapy in tissue culture, using T-47D as a model system. METHODS AND MATERIALS: T-47D cells were incubated in medium containing 0 nM to 1 nM silvestrol either for 24 h prior to irradiation at 0 Gy to 10 Gy, delivered by linear accelerator (LINAC) or continually for six days post irradiation. MTT viability and clonogenic assays were used to quantify response. RESULTS: Pre-treatment of T-47D cells with 1 nM silvestrol caused a 34% reduction (p = 0.014) in viability on irradiation at 2 Gy compared to treatment with a DMSO control, as assessed by MTT assay. Maintenance of cells in 1 nM silvestrol for six days following irradiation at 2 Gy caused a 58% reduction (p = <0.001) in tumor cell viability. Clonogenic assays performed on cells maintained in 1 nM silvestrol following irradiation showed a dose modifying factor (DMF) of 1.4 (p = <0.001, one-way ANOVA). CONCLUSIONS: Low concentrations of silvestrol sensitize T-47D breast cancer cells to radiation with minimal effects on unirradiated cells. This highlights the possible usefulness of eIF4A inhibition in potentiating radiation-induced damage at the tumor site without causing systemic toxicity. Elsevier 2020-07-24 /pmc/articles/PMC7451755/ /pubmed/32875125 http://dx.doi.org/10.1016/j.ctro.2020.07.002 Text en © 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Webb, Thomas E.
Davies, Marc
Maher, John
Sarker, Debashis
The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy
title The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy
title_full The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy
title_fullStr The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy
title_full_unstemmed The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy
title_short The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy
title_sort eif4a inhibitor silvestrol sensitizes t-47d ductal breast carcinoma cells to external-beam radiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451755/
https://www.ncbi.nlm.nih.gov/pubmed/32875125
http://dx.doi.org/10.1016/j.ctro.2020.07.002
work_keys_str_mv AT webbthomase theeif4ainhibitorsilvestrolsensitizest47dductalbreastcarcinomacellstoexternalbeamradiotherapy
AT daviesmarc theeif4ainhibitorsilvestrolsensitizest47dductalbreastcarcinomacellstoexternalbeamradiotherapy
AT maherjohn theeif4ainhibitorsilvestrolsensitizest47dductalbreastcarcinomacellstoexternalbeamradiotherapy
AT sarkerdebashis theeif4ainhibitorsilvestrolsensitizest47dductalbreastcarcinomacellstoexternalbeamradiotherapy
AT webbthomase eif4ainhibitorsilvestrolsensitizest47dductalbreastcarcinomacellstoexternalbeamradiotherapy
AT daviesmarc eif4ainhibitorsilvestrolsensitizest47dductalbreastcarcinomacellstoexternalbeamradiotherapy
AT maherjohn eif4ainhibitorsilvestrolsensitizest47dductalbreastcarcinomacellstoexternalbeamradiotherapy
AT sarkerdebashis eif4ainhibitorsilvestrolsensitizest47dductalbreastcarcinomacellstoexternalbeamradiotherapy